Premium
Distortion product otoacoustic emission for the screening of cochlear damage in children treated with cisplatin
Author(s) -
AlNoury Khaled
Publication year - 2011
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1002/lary.21740
Subject(s) - audiogram , otoacoustic emission , audiology , medicine , audiometry , ototoxicity , pure tone audiometry , hearing loss , cisplatin , chemotherapy
Objectives/Hypothesis: To detect subtle hearing changes by measuring otoacoustic emissions in patients treated with a first dose of cisplatin. Study Design: Prospective study. Methods: We recruited 26 patients (mean age at treatment, 11.3 years) into this prospective study conducted at a tertiary academic referral center. Audiograms and transient‐evoked otoacoustic emissions (TEOAEs) and distortion‐product otoacoustic emissions (DPOAEs) were measured before and after the first dose of cisplatin. Results: Baseline readings were compared with those recorded after the administration of the first dose of cisplatin. Two patients showed a loss of TEOAEs at high frequencies above 4 kHz, and this was consistent with the 25‐dB hearing loss of the high frequencies detected in their audiograms; there was a significant threshold shift for DPOAEs at a frequency >3 to 4 kHz ( P <.05). Conclusions: DPOAE testing appears to be a more sensitive method to detect cochlear damage than conventional pure‐tone audiometry. Our results suggest that the measurement of DPOAE thresholds is a useful approach to detect the early auditory changes induced by cisplatin therapy.